文献速递中枢神经肿瘤放疗放疗物理与技术

单次立体定向放射外科治疗多发性脑转移瘤

Single fraction stereotactic radiosurgery for multiple brain metastases.
PubMed 文献 · Adv Radiat Oncol · 2017-09-11

本回顾性单中心研究纳入2013年1月至2015年9月接受单次直线加速器立体定向放射外科(SRS)治疗≥4个脑转移瘤的59例患者,中位随访15.2个月,中位总生存5.8个月;总计划靶体积(PTV)<10 cc、全PTV平均剂量≥19 Gy及正常脑接受>12 Gy体积较小与生存改善相关。

要点

  • 单次SRS治疗≥4个脑转移瘤,中位总生存5.8个月。
  • 总PTV<10 cc较≥10 cc生存更优(7.1 vs 4.2个月,P=.0001)。
  • 全PTV平均剂量≥19 Gy与生存改善相关(6.6 vs 5.0个月,P=.0172)。

核心结论

  • 单次SRS治疗多发性脑转移瘤中,较小总肿瘤体积、较高总剂量及较低正常脑接受>12 Gy体积与生存增加相关。
  • 数据提示SRS治疗多发性脑转移瘤有效,结局可能更多受总肿瘤体积而非病灶数量影响。

研究设计与样本

  • 经机构审查委员会批准的回顾性单中心研究,纳入2013年1月1日至2015年9月30日接受单次SRS治疗≥4个脑转移瘤的全部患者。
  • 患者接受基于直线加速器的图像引导SRS,共59例患者、380个脑转移瘤。

主要发现

  • 中位随访15.2个月,整个队列中位总生存5.8个月。
  • 每患者中位治疗病灶数5个(范围4-23),每患者中位PTV为4.8 cc(范围0.7-28.8 cc)。
  • 380个脑转移瘤的处方剂量范围为7至20 Gy,全PTV平均剂量的中位值为19.5 Gy。
  • 治疗病灶数(4-5 vs ≥6)不影响生存,但总PTV<10 cc vs ≥10 cc生存更优(7.1 vs 4.2个月,P=.0001)。
  • 全PTV平均剂量≥19 Gy vs <19 Gy与生存增加相关(6.6 vs 5.0个月,P=.0172);正常脑接受>12 Gy剂量体积≥10 cc vs <10 cc生存更差(5.1 vs 8.6个月,P=.0028)。

关键数值与推荐

  • 总PTV<10 cc较≥10 cc与更好生存相关(7.1 vs 4.2个月,P=.0001)。
  • 全PTV平均剂量≥19 Gy较<19 Gy与生存增加相关(6.6 vs 5.0个月,P=.0172)。
  • 正常脑接受>12 Gy的剂量体积≥10 cc较<10 cc与更差生存相关(5.1 vs 8.6个月,P=.0028)。

临床怎么用

  • 对多发性脑转移瘤患者行单次SRS时,可关注总肿瘤体积而非仅病灶数量来评估预后。
  • 在满足正常脑剂量约束前提下,可考虑提高全PTV平均剂量以改善生存。
  • 应尽量降低正常脑接受>12 Gy的剂量体积。

局限性

  • 回顾性单中心研究,样本量59例。
  • 中位随访15.2个月,中位总生存仅5.8个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Due to the neurocognitive side effects of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) is being used with increasing frequency. The use of SRS is expanding for patients with multiple (>4) brain metastases (BM). This study summarizes our institutional experience with single-fraction, linear-accelerator-based SRS for multiple BM. METHODS AND MATERIALS: All patients who were treated between January 1, 2013, and September 30, 2015, with single-fraction SRS for ≥4 BM were included in this institutional review board-approved, retrospective, single-institution study. Patients were treated with linear accelerator-based image guided SRS. RESULTS: A total of 59 patients with ≥4 BM were treated with single-fraction SRS. The median follow-up was 15.2 months, and the median overall survival for the entire cohort was 5.8 months. The median number of treated lesions per patient was 5 (range, 4-23). Per patient, the median planning target volume (PTV) was 4.8 cc (range, 0.7-28.8 cc). The prescribed dose across all 380 BM for the 59 patients ranged from 7 to 20 Gy. The median of the mean dose to the total PTV was 19.5 Gy. Although the number of treated lesions (4-5 vs ≥6) did not influence survival, better survival was noted for a total PTV <10 cc versus ≥10 cc (7.1 vs 4.2 months, respectively; P = .0001). A mean dose of ≥19 Gy to the entire PTV was also associated with increased survival (6.6 vs 5.0 months, respectively; P = .0172). Patients receiving a dose of >12 Gy to ≥10 cc of normal brain had worse survival (5.1 vs 8.6 months, respectively; P = .0028). CONCLUSION: In single-fraction SRS for patients with multiple BM, smaller total tumor volume, higher total dose, and lower volume of normal brain receiving >12 Gy were associated with increased survival. These data suggest that using SRS for the treatment of multiple BM is efficacious and that outcomes may be affected more by total tumor volume than by the number of lesions.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Limon D, McSherry F, Herndon J, et al. Single fraction stereotactic radiosurgery for multiple brain metastases. Adv Radiat Oncol. 2017. PMID: 29204522. doi:10.1016/j.adro.2017.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。